Quantitative analysis substantiated the recovery of the MLVs as the investigation of LYVE-1 density and MLV length revealed no significant difference at hotspots in the TS area and COS areas between PBSL and CLL treatments (Figure 3, C–E). Here, LYVE1 is linked to B-cell chronic lymphocytic leukemia.